| Company/Division name | Taysha Gene Therapies |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2023 |
| Capital investment ($): | 75 |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy, adeno-associated virus serotype 9 |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Lead time/Time to market, Lean/other business process improvement techniques, Skilled workforce availability/training |
